

WARD 24|7

Transform how hospital patients are monitored.

**Betina Langemark, CEO
BioInnovation Institut
Demo day 27 May 2020**



30%

of patients have
unexpected critical
complications

3rd

leading cause of
death (surgery),
WHO

95%


of warning
signs are
undetected

4-6 days


prolonged stay in
hospital after
complications



Vision: From infrequent manual monitoring to 24/7 AI based early warning of complications



Our solution: Patient monitoring transformed



INTELLIGENT ALGORITHMS translate vital signs from standard wireless devices into clinically meaningful **ALERTS**

INTUITIVE INTERFACES provide unique overview of patients so nurses can focus and **REACT** when needed

The future: Detect complications earlier

Helping patients get the best care

Helping nurses know when to act

Helping hospitals save costs



Even 1st generation WARD 24/7 gives +12 hours to change patient outcome

Uncomplicated colon resection

Dizziness and feeling weak

WARD alert:
Two dimensional AI interpretation detects deteriorating circulation

CT scan reveals anastomotic leak

Re-operated

Day 1


**Day 2
02.00**

**Day 2
14.00**

**Day 2
21.00**



No players can develop AI real-time prediction yet



Our commercial roadmap

Academic foundation

4M € grant
700 ptt clinical trial
TRL-8 in 2020

Clinical trial data collection

Learning

In-hospital patient monitoring with alerts

Market entry

In-hospital predictive clinical support system

Scale up

Out-patient monitoring (post discharge)

Long-term vision



Ongoing
4/5 DK Regions
COVID-19

2021
launch

2022
launch

2022/23
launch

2023/24
launch

Substantial market size & peak sales potential

25 B USD

Patient monitoring device market 2023 (cagr 5.7%)

Business model

Multiple device company collaboration w easy calibration
Use fee per patient per day + service

150-350 M USD

Patient subscription **peak sales potential**


Assumptions:

2M curative beds US+EU12, 25% eligible, 10 USD per pt per day, 10% market share, 80% occupation

Market entry

Market entry in large academic hospitals
Initial focus on isolation and innovation

Product roadmap towards first launch 2022



A complimentary team



Helge Bjarup Dissing Sørensen

Assoc. Professor MSK, PhD

Founder & CTO

Artificial Intelligence

Bioengineering



Christian S. Meyhoff

MD PhD

Founder & CMO

Anaesthesiology

Patient monitoring

Intensive care

Clinical research



Eske K. Aasvang

MD PhD

Founder & CRDO

Anaesthesiology

Post-surgery care and

complicaitons

Clinical research



Betina Langemark

MSc

CEO

20 years big pharma & biotech

Novo Nordisk, Abbvie,

Astra Zenaca

Strategy, BD, R&D, operations

**Thank you for
your attention.**



WARD 24|7

**Please don't
hesitate to
contact us**



Betina Langemark

+45 29112134

betina.langemark@ward247.com

www. WARD247.com